Alex Ganetsky
YOU?
Author Swipe
View article: Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature
Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature Open
View article: Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study
Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study Open
View article: Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America
Employment, Insurance, and Financial Experiences of Patients with Chronic Graft-versus-Host Disease in North America Open
Understanding the socioeconomic impact of chronic graft-versus-host disease (GVHD) on affected patients is essential to help improve their overall well-being. Using data from the Chronic GVHD Consortium, we describe the insurance, employme…
View article: Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients
Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients Open
Prophylaxis with oral vancomycin is highly effective in preventing CDI in alloHCT recipients without increasing the risk of graft-versus-host disease or disease relapse. Further evaluation via a prospective study is warranted.
View article: Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer
Drug-Drug Interactions, Safety, and Pharmacokinetics of EGFR Tyrosine Kinase Inhibitors for the Treatment of Non–Small Cell Lung Cancer Open
Inhibitors of the epidermal growth factor receptor (EGFR) are important treatment options for non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. Erlotinib, gefitinib, afatinib, and osimertinib are approved f…
View article: Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12
Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12 Open
Adoptive T cell therapy (ACT) is a promising new modality for malignancies. Here, we report that adoptive T cell efficacy in tumor-bearing mice is significantly affected by differences in the native composition of the gut microbiome or tre…
View article: Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease
Employment, Insurance and Financial Experiences of Patients with Chronic Graft-Versus-Host Disease Open
Background: Understanding the socioeconomic impact of chronic GVHD (cGVHD) is essential to help improve the overall well-being of affected patients. Using data from the cGVHD Consortium, we describe the insurance, employment and financial …
View article: Long-Term Outcomes of Rituximab, Temozolomide and High-Dose Methotrexate Without Consolidation Therapy for Lymphoma Involving the CNS
Long-Term Outcomes of Rituximab, Temozolomide and High-Dose Methotrexate Without Consolidation Therapy for Lymphoma Involving the CNS Open
The rituximab, temozolomide and methotrexate regimen is an effective therapy for patients with PCNSL without the toxicities typically associated with consolidation therapy.
View article: Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis
Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis Open
Blocking lymphocyte trafficking after allogeneic hematopoietic stem cell transplantation is a promising strategy to prevent graft-versus-host disease (GVHD) while preserving the graft-versus-tumor response. Maraviroc, a CCR5 antagonist, ha…
View article: A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data
A validation of clinical data captured from a novel Cancer Care Quality Program directly integrated with administrative claims data Open
Good agreement between the HIRE-Oncology data and medical records supports the validity of these data for research.
View article: Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients
Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients Open
Hematopoietic cell transplantation (HCT) is an expensive, medically complicated, and potentially life-threatening therapy for multiple hematologic and nonhematologic disorders with a prolonged trajectory of recovery. Similar to financial i…
View article: Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study
Extended Course of Maraviroc, a CCR5 Antagonist, Is Safe and Effective in Graft-Versus-Host Disease Prophylaxis. Final Results of a Phase II Study Open
Background: Blocking lymphocyte migration may prevent GvHD without interfering with graft-versus-tumor activity. We previously reported that brief (up to day+30) CCR5 blockade using maraviroc (MVC) resulted in a low incidence of acute GvHD…
View article: Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia
Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia Open
To the editor:
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder partly dependent on the B-cell receptor (BCR) signaling pathway. The novel BCR signal transduction inhibitor ibrutinib has emerged as an effective …
View article: Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation
Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation Open
View article: Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T‐cell acute lymphoblastic leukaemia and lymphoma
Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T‐cell acute lymphoblastic leukaemia and lymphoma Open
Despite improvements in first-line treatment of T-cell acute lymphoblastic leukaemia (T-ALL) and lymphoma (T-LBL), the prognosis for patients with primary refractory or relapsed T-ALL/T-LBL remains dismal. Fewer than 10% of these patients …
View article: Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients
Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients Open
Objectives Emerging data suggest that the combination of tacrolimus and the CCR5 antagonist maraviroc, both cytochrome P450-3A4 substrates, may be effective in preventing graft-versus-host disease in patients undergoing allogeneic HSCT. Th…
View article: Higher Tacrolimus Concentrations Early Post-Transplant Reduce the Risk of Acute Graft-Versus-Host Disease in Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation
Higher Tacrolimus Concentrations Early Post-Transplant Reduce the Risk of Acute Graft-Versus-Host Disease in Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Open
Tacrolimus (TAC) remains the backbone of graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic stem cell transplantation (HSCT). There is significant variability in the serum concentrations of TAC attained early post-tra…